J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

Johnson & Johnson and Protagonist Therapeutics announced two Phase 3 successes for their oral IL-23 drug, showcasing the first results out of an expansive pivotal trial program in plaque psoriasis. J&J